

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 05th September 2025 FOI Ref 30201

Requested Information:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

Response:

During June to August 2025, Royal Cornwall Hospitals Trust Rheumatology Department treated the following numbers with the following drugs:

- Abatacept [Orencia] **37**
- Adalimumab [Humira] **30**
- Adalimumab Biosimilars **741**
- Apremilast [Otezla] **14**
- Baricitinib [Olumiant] **56**
- Bimekizumab [Bimzelx] **4**
- Certolizumab [Cimzia] **98**
- Etanercept [Enbrel] **14**
- Etanercept Biosimilars **160**
- Filgotinib [Jyseleca] **116**
- Golimumab [Simponi] **35**
- Guselkumab [Tremfya] **2**
- Infliximab [Remicade] **1**
- Infliximab Biosimilars **35**
- Ixekizumab [Taltz] **23**
- Risankizumab [Skyrizi] **1**
- Rituximab [MabThera] **3**
- Rituximab Biosimilars **63**
- Sarilumab [Kevzara] **21**
- Secukinumab [Cosentyx] **121**
- Tocilizumab [Ro Actemra] **6**
- Tocilizumab Biosimilars **107**
- Tofacitinib [Xeljanz] **54**
- Upadacitinib [Rinvoq] **104**
- Ustekinumab [Stelara] **0**
- Ustekinumab Biosimilar **10**

Attachment(s):

No Attachment(s)

Date Response sent: 12th September 2025